The Journal of Allergy and Clinical Immunology, March 2017, Vol.139(3), pp.1052-1055
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jaci.2016.08.041 Byline: Rebecca Z. Krouse (a), Christine A. Sorkness (b), Jeremy J. Wildfire (a), Agustin Calatroni (a), Rebecca Gruchalla (c), Gurjit K. Khurana Hershey (d), Meyer Kattan (e), Andrew H. Liu (f)(g), Melanie Makhija (h), Stephen J. Teach (i), Joseph B. West (j), Robert A. Wood (k), Edward M. Zoratti (l), Peter J. Gergen (m) Author Affiliation: (a) Rho Federal Systems Division, Inc, Chapel Hill, NC (b) University of Wisconsin School of Medicine and Public Health, Madison, Wis (c) University of Texas Southwestern Medical Center, Dallas, Tex (d) Cincinnati Children's Hospital, Cincinnati, Ohio (e) College of Physicians and Surgeons, Columbia University, New York, NY (f) National Jewish Health, Denver, Colo (g) Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colo (h) Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Ill (i) Children's National Health System, Washington, DC (j) Boston University School of Medicine, Boston, Mass (k) Johns Hopkins University School of Medicine, Baltimore, Md (l) Henry Ford Health System, Detroit, Mich (m) National Institute of Allergy and Infectious Diseases, Bethesda, Md Article Note: (footnote) This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (contract nos. HHSN272200900052C, HHSN272201000052I, and 1UM1AI114271-01). Additional support was provided by the National Center for Research Resources, and National Center for Advancing Translational Sciences, NIH (grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075, UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). Glaxo SmithKline (GSK) provided Ventolin, Flovent, Advair, and Flonase under a clinical trial agreement with NIH-NIAID; GSK did not have a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit the manuscript for publication., Disclosure of potential conflict of interest: R. Z. Krouse receives research support from the National Institutes of Health (NIH)-National Institute of Allergy and Infectious Diseases (NIAID). C. A. Sorkness receives research support from the NIH-NIAID and Novartis. J. J. Wildfire receives research support from the NIH-NIAID. A. Calatroni receives research support from the NIH-NIAID. R. Gruchalla serves as a consultant for Massachusetts Medical Society. G. K. K. Hershey receives grant support from the NIH. M. Kattan receives research support from the NIH-NIAID and serves on the board for Novartis Pharma. A. H. Liu receives research support from the NIH; has board membership for GlaxoSmithKine; and receives payments for lectures from Merck. M. Makhija receives research support from the NIH. S. J. Teach receives research support from the NIH-NIAID, PCORI, Fight for Children Foundation and EJF Philanthropies, and Novartis; serves as consultant for Novartis; and receives royalties from UpToDate. J. B. West receives research support from the NIH-NIAID. R. A. Wood receives research support from the NIH, DBV, and Aimmune; serves as a consultant for Sanofi and Stallergenes; and receives royalties from UpToDate. E. M. Zoratti receives research support from the NIH-NIAID. The rest of the authors declare that they have no relevant conflicts of interest.
View record in ScienceDirect (Access to full text may be restricted)